Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31348948 | 1.00 | HDAC1 (0.48) | HDAC1HDAC2KLK7KLK5TNF | |
| SCHEMBL31348954 | 1.00 | HDAC1 (0.48) | HDAC1HDAC2KLK7KLK5TNF | |
| SCHEMBL27128254 | 1.00 | HDAC1 (0.48) | HDAC1HDAC2KLK7KLK5TNF | |
| SCHEMBL29554781 | 1.00 | HDAC1 (0.48) | HDAC1HDAC2KLK7KLK5TNF | |
| SCHEMBL15883745 | 1.00 | HDAC1 (0.48) | HDAC1HDAC2KLK7KLK5TNF | |
| SCHEMBL20418498 | 0.92 | KLK7 (0.52) | HDAC1HDAC2KLK7KLK5TNF | |
| SCHEMBL29447512 | 0.92 | KLK7 (0.52) | HDAC1HDAC2KLK7KLK5TNF | |
| SCHEMBL14728042 | 0.90 | HDAC1 (0.51) | HDAC1HDAC2TNFMDM4TP53 | |
| SCHEMBL29768867 | 0.90 | HDAC1 (0.51) | HDAC1HDAC2TNFMDM4TP53 | |
| SCHEMBL15883749 | 0.89 | CASP3 (0.48) | CACNA1BCASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025005639-A1 | CATIONIC AMPHIPHILIC POLYPEPTIDE FOR RNA DELIVERY AND MANUFACTURING METHOD THEREOF | 인하대학교 산학협력단 | 2025-01-02 | — | — | WO | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022194399-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | HDAC1 1543/4885HDAC2 2131/4885KLK7 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.